Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012)

Summary

This study will assess the safety, tolerability, pharmacokinetics, and glucose lowering activity of MK-8245 in participants with type 2 diabetes. The primary hypothesis of the study is that after 4 weeks of treatment, MK-8245 produces a greater reduction in 24 hour weighted mean glucose (WMG) from baseline than placebo.

Timeline

Start

2009-08-24

Primary completion

2010-01-12

Completion

2010-01-26

Outcome

Missed primary endpoint

registry MK-8245 100 mg vs Placebo; p = 0.083; Mean Difference (Final Values) -15.34 (90% CI -29.87 to -0.82) NCT00972322 ↗

Drugs

Indications